• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Therapy of severe aplastic anemia with anti-human thymocyte globulin (ATGAM) with and without HLA-haploidentical bone-marrow infusion.采用抗人胸腺细胞球蛋白（ATGAM）联合或不联合HLA单倍型相合骨髓输注治疗重型再生障碍性贫血。
J Korean Med Sci. 1986 Sep;1(1):37-41. doi: 10.3346/jkms.1986.1.1.37.
2
Treatment of severe aplastic anemia using antithymocyte globulin with or without an infusion of HLA haploidentical marrow.使用抗胸腺细胞球蛋白联合或不联合输注人类白细胞抗原单倍型相合骨髓治疗重型再生障碍性贫血。
Exp Hematol. 1981 Sep;9(8):829-34.
3
Therapy of severe aplastic anemia with anti-human thymocyte globulin and androgens: the effect of HLA-haploidentical marrow infusion.用抗人胸腺细胞球蛋白和雄激素治疗重型再生障碍性贫血：HLA单倍型相合骨髓输注的效果
Blood. 1984 Feb;63(2):342-8.
4
Anti-thymocyte globulin treatment for aplastic anemia.抗胸腺细胞球蛋白治疗再生障碍性贫血。
Scand J Haematol. 1982 Apr;28(4):341-51. doi: 10.1111/j.1600-0609.1982.tb00536.x.
5
Immunosuppressive therapy versus bone marrow transplantation for children with aplastic anemia.再生障碍性贫血患儿免疫抑制治疗与骨髓移植的对比
Pediatrics. 1989 Jan;83(1):61-5.
6
Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia.骨髓移植与抗胸腺细胞球蛋白治疗年轻重型再生障碍性贫血患者的比较。
J Pediatr. 1984 Dec;105(6):920-5. doi: 10.1016/s0022-3476(84)80078-5.
7
Treatment of severe aplastic anemia: comparison of bone marrow transplantation to immunotherapy.重型再生障碍性贫血的治疗：骨髓移植与免疫疗法的比较。
Zhonghua Yi Xue Za Zhi (Taipei). 1989 Jan;43(1):21-8.
8
Successful bone marrow transplantation with rabbit anti-human thymocyte globulin in aplastic anemia. Report of a case previously treated with equine anti-human lymphocyte globulin.兔抗人胸腺细胞球蛋白用于再生障碍性贫血的成功骨髓移植。1例先前接受马抗人淋巴细胞球蛋白治疗的病例报告。
Int J Hematol. 1994 Jul;60(1):79-83.
9
Antithymocyte globulin: a realistic approach to therapy for severe aplastic anemia.
South Med J. 1986 Sep;79(9):1121-5.
10
Treatment of severe aplastic anaemia with anti-thymocyte globulin.用抗胸腺细胞球蛋白治疗重型再生障碍性贫血。
Acta Haematol. 1985;74(3):144-7. doi: 10.1159/000206190.

引用本文的文献

1
Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study.单倍体相合骨髓移植及移植后环磷酰胺治疗重型再生障碍性贫血：一项多中心回顾性研究
Bone Marrow Transplant. 2015 May;50(5):685-9. doi: 10.1038/bmt.2015.20. Epub 2015 Mar 2.

采用抗人胸腺细胞球蛋白（ATGAM）联合或不联合HLA单倍型相合骨髓输注治疗重型再生障碍性贫血。

Therapy of severe aplastic anemia with anti-human thymocyte globulin (ATGAM) with and without HLA-haploidentical bone-marrow infusion.

作者信息

Kim K Y

机构信息

Department of Pediatrics, Yonsei University, College of Medicine Seoul, Korea.

出版信息

J Korean Med Sci. 1986 Sep;1(1):37-41. doi: 10.3346/jkms.1986.1.1.37.

DOI:10.3346/jkms.1986.1.1.37
PMID:2856584
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3053608/
Abstract

Six patients with severe aplastic anemia treated with horse anti-human thymocyte globulin (ATG) and androgen. Four of these patients were only given ATG (ATGAMR), 16 mg/Kg/dose x 10 doses. The remaining two cases received an infusion of maternal HLA-haploidentical marrow cells following ATG therapy. One patient had a complete response, three had a partial response, one showed minimal improvement and two were non-responders. The two patients who received the additional haploidentical marrow cells showed a hematologic recovery sooner than the ATG alone cases. The toxicity of the ATG therapy was tolerable. Long term follow up of there patients and further studies of this treatment in aplastic anemia with pediatric age group are under way.

摘要

6例重型再生障碍性贫血患者接受了马抗人胸腺细胞球蛋白（ATG）和雄激素治疗。其中4例患者仅接受了ATG（ATGAMR）治疗，剂量为16mg/kg/剂量，共10剂。其余2例患者在ATG治疗后接受了母亲单倍型相合骨髓细胞输注。1例患者完全缓解，3例部分缓解，1例有轻微改善，2例无反应。接受额外单倍型相合骨髓细胞的2例患者血液学恢复比单纯接受ATG治疗的患者更快。ATG治疗的毒性是可耐受的。目前正在对这些患者进行长期随访，并在儿童年龄组的再生障碍性贫血中对该治疗进行进一步研究。